To evaluate the value of combined detection of serum @entity787 , CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS for the clinical diagnosis of @entity1820 and to analyze the efficacy of these @entity5 markers (TMs) in evaluating curative effects and prognosis. A total of 573 @entity1 with @entity1820 between January 2004 and December 2007 were enrolled in this study. Serum levels of @entity787 , CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were examined preoperatively and every 3 months postoperatively by ELISA. The sensitivity of @entity787 , CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were 26.8%, 36.2%, 42.9%, 2.84%, 25.4%, 34.6%, 34.2% and 30.9%, respectively. The combined detection of @entity787 +CA199+CA242+CA724 had higher sensitivity and specificity in @entity356 ( @entity356 ) and @entity4617 , while @entity787 +CA199+CA242+SCC was the best combination of diagnosis for @entity418 ( @entity418 ). Elevation of preoperative @entity787 , CA19-9 and CA24-2, SCC and CA72-4 was significantly associated with pathological types (p<0.05) and TNM staging (p<0.05). Correlation analysis showed that CA24-2 was significantly correlated with CA19-9 (r=0.810, p<0.001). The levels of @entity787 , CA19-9, CA24-2, CA72-4 and SCC decreased obviously 3 months after operations. When @entity3 and recurrence occurred, the levels of TMs significantly increased. On multivariate analysis, high preoperative CA72-4, CA24-2 and SCC served as prognostic factors for @entity4617 , @entity356 and @entity418 , respectively. combined detection of @entity787 +CA199+CA242+SCC proved to be the most economic and practical strategy in diagnosis of @entity418 ; @entity787 +CA199+CA242+CA724 proved to be a better evaluation indicator for @entity4617 and @entity356 . @entity787 and CA19-9, CA24-2, CA72-4 and SCC, examined postoperatively during follow-up, were useful to find @entity5 recurrence and @entity3 , and evaluate prognosis. AFP, TPA and TPS have no significant value in diagnosis of @entity1 with @entity1820 .

Tumor markers for diagnosis, monitoring of recurrence and prognosis in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'early tumor'] @entity4617 :: ('MESH:D006338', 'Disease') :: ['cardiac carcinoma', 'cardiac cancer'] @entity787 :: ('1084', 'Gene') :: ['CEA'] @entity1820 :: ('MESH:D005770', 'Disease') :: ['upper gastrointestinal tract (GIT) cancer', 'upper GIT cancer'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer', 'EC'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'GC']
@entity1820 :: (MESH:D005770,Disease) :: ['upper gastrointestinal tract cancer']
